Immunome Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
IMNM$19.36+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
5. Balance sheet components
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Manufacturing expenses | $12,326 | $9,462 |
| Compensation and related benefits | 10,241 | 11,527 |
| Clinical development expenses | 8,718 | 7,036 |
| Operating lease liabilities, current portion | 1,127 | — |
| Development milestones | 986 | 10,000 |
| Other | 3,107 | 3,626 |
| Total accrued expenses and other current liabilities | $36,505 | $41,651 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.